Actinium Pharmaceuticals vs Kazia Therapeutics
ATNM and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATNM and KZIA compare
Actinium Pharmaceuticals scores higher on the StockData Score (10 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATNM | KZIA |
|---|---|---|
| Size and price | ||
| Market cap | $42.4M | – |
| Share price | $1.35 | $5.31 |
| Change, 1 year | 6.3% | −15.3% |
| Change, 5 years | −81.5% | −98.9% |
| Beta (5Y) | 1.38 | 4.08 |
| Employees | 25 | 14 |
| StockData Score | ||
| Total score | 10 (better) | 1 |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 3.8× | – |
| P/B | 1.4× | – |
| EV/EBITDA | 0.6× | – |
| Fair value | $7.16 | – |
| Margin of safety | 81.1% | – |
| Growth | ||
| Revenue growth (TTM) | – | −98.2% |
| Profitability | ||
| Net margin | – | −49291% |
| Return on equity | 45.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 4.08 (better) | 2.87 |
| Altman Z-score | −9.28 | – |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 16.8% | 0.45% |
| Held by insiders | 5.9% | 0.29% |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.0% | – |
Go deeper
- ATNM stock overview
- ATNM income statement
- ATNM valuation and score
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.